Cancer research is integral to discovering and developing new treatments for lymphoma patients. It is because of ongoing research that there are more and newer approaches to diagnosing and treating lymphoma. Research is integral to the development of Canadian, national guidelines for the treatment of lymphoma. Treatment guidelines provide valuable information and guidance for healthcare professionals (HCPs) , and patients in that they establish a national standard in the treatment of lymphoma. Not only do these guidelines result in a better understanding of treatment options but also of recommended approaches to treatments based on available therapies in Canada.
Over the years, Lymphoma Canada has continued to work with members of our Scientific Advisory Board as well as specialists (hematologists, medical oncologists, radiation oncologists) across the country to develop guidelines for treatment approaches in the first line and relapsed/refractory settings for specific lymphoma subtypes.
Canadian Evidence-Based Guideline for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
This year, following the recent publication of Canadian evidence-based guidelines for frontline treatment CLL, Lymphoma Canada worked alongside clinicians to develop guidelines for CLL in the relapsed/refractory (R/R) setting. The treatment of R/R CLL has changed significantly in the past few years, with many novel therapeutics available to hematologists across the country. These guidelines aim to standardize the management of CLL in the relapsed/refractory setting, using the best evidence currently available.
Other Treatment Guidelines
To date, Lymphoma Canada in collaboration with the health care professionals has also developed the following evidence-based treatment guidelines (click to view their pages and learn more):
Lymphoma Canada will continue to work alongside the lymphoma community in the continued development of national treatment guidelines. In fact, we will be working on the following in the near future:
- National Guidelines in the Treatment of Hodgkin Lymphoma in the Frontline & Relapsed/Refractory settings
- Updates to existing guidelines – to ensure the treatment algorithms are up to date and incorporate newer therapeutics
Since our inception in 1998, Lymphoma Canada has funded annually, research programs supporting, well-defined research studies that have the potential to effect improvements in healthcare, health systems, and/or health outcomes as they pertain to malignant lymphoproliferative diseases. This has been a proud part of who Lymphoma Canada is since we were founded.
2023 grant recipients will be announced soon.
Contribute to help us continue our journey
Lymphoma Canada relies on the generosity of supporters like you, to continue advancing our mission of empowering patients and the Canadian lymphoma community through education, support, advocacy, and research.